全文获取类型
收费全文 | 6455篇 |
免费 | 2531篇 |
国内免费 | 33篇 |
专业分类
耳鼻咽喉 | 189篇 |
儿科学 | 240篇 |
妇产科学 | 206篇 |
基础医学 | 123篇 |
口腔科学 | 40篇 |
临床医学 | 1100篇 |
内科学 | 1894篇 |
皮肤病学 | 432篇 |
神经病学 | 608篇 |
特种医学 | 219篇 |
外科学 | 2146篇 |
综合类 | 12篇 |
预防医学 | 544篇 |
眼科学 | 539篇 |
药学 | 107篇 |
中国医学 | 4篇 |
肿瘤学 | 616篇 |
出版年
2024年 | 55篇 |
2023年 | 677篇 |
2022年 | 85篇 |
2021年 | 274篇 |
2020年 | 381篇 |
2019年 | 153篇 |
2018年 | 655篇 |
2017年 | 723篇 |
2016年 | 626篇 |
2015年 | 579篇 |
2014年 | 768篇 |
2013年 | 697篇 |
2012年 | 316篇 |
2011年 | 294篇 |
2010年 | 475篇 |
2009年 | 627篇 |
2008年 | 245篇 |
2007年 | 114篇 |
2006年 | 177篇 |
2005年 | 96篇 |
2004年 | 68篇 |
2003年 | 65篇 |
2002年 | 62篇 |
2001年 | 104篇 |
2000年 | 45篇 |
1999年 | 68篇 |
1998年 | 83篇 |
1997年 | 90篇 |
1996年 | 63篇 |
1995年 | 61篇 |
1994年 | 38篇 |
1993年 | 34篇 |
1992年 | 39篇 |
1991年 | 34篇 |
1990年 | 19篇 |
1989年 | 18篇 |
1988年 | 21篇 |
1987年 | 11篇 |
1986年 | 8篇 |
1985年 | 4篇 |
1984年 | 5篇 |
1983年 | 9篇 |
1982年 | 12篇 |
1981年 | 10篇 |
1980年 | 7篇 |
1979年 | 3篇 |
1978年 | 3篇 |
1977年 | 4篇 |
1972年 | 2篇 |
1971年 | 3篇 |
排序方式: 共有9019条查询结果,搜索用时 15 毫秒
991.
992.
993.
Sarah E. Bowater MBBS Rebekah A. Weaver MSc Sara A. Thorne MD Paul F. Clift MD 《Congenital heart disease》2012,7(3):243-249
Objective. Adult patients with a Fontan circulation tend to have diminished exercise capacity. The principal objective of this study was to investigate the safety of the endothelin receptor antagonist bosentan in Fontan patients, and, secondarily, to assess effects on cardiovascular performance, New York Heart Association functional classification (NYHA FC), and ventricular function. Design. A 6‐month prospective, single‐center, pilot, safety study of bosentan in Fontan patients. Setting. Adult Congenital Heart Disease referral center. Patients. All patients ≥18 years old with a Fontan circulation and in NYHA FC ≥II were invited to enroll. Interventions. Patients started on 62.5 mg bid of bosentan, uptitrating to 125 mg bid after 2 weeks. Outcome Measures. Safety was assessed by the incidence of anticipated and unanticipated adverse events during the 6‐month study period; specifically those relating to hepatic, renal, or hematological dysfunction as measured by monthly blood tests. Other outcome measures included cardiopulmonary exercise test, 6‐minute walk distance test, Borg dyspnea index, NYHA FC, and ventricular function parameters using transthoracic echocardiography. Results. Of the eight patients enrolled, six completed the study. Two patients withdrew from the study (one for non–trial related reasons, one due to adverse events). No clinically significant adverse events relating to bosentan therapy occurred during this study and, in particular, no significant abnormalities in hepatic function tests were observed. Three patients reported transient adverse events. Improvements in NYHA FC and systolic ventricular function were observed after 6 months of bosentan treatment. Conclusions. The small number of patients with a Fontan circulation in our study was able to tolerate bosentan for 6 months. The safety and tolerability of bosentan in a larger patient population remains unknown. The results presented here justify further investigation in larger studies. 相似文献
994.
995.
Shoulder pain is the third most common musculoskeletal problem and accounts for 5% of general practitioner consultations. Although many treatments are described, there is no consensus on optimal treatment and up to 40% of patients still have pain 12 months after initially seeking help for pain. Previously, the effect of transcutaneous pulsed radiofrequency treatment (TCPRFT) was evaluated in a retrospective audit that showed good pain relief for a mean 395 days and justified this randomized sham controlled trial. In this study, 51 patients entered into a randomized double‐blinded, placebo controlled study of TCPRFT. Patients were assessed at 4 and 12 weeks by a blinded observer and compared with baseline. We observed sustained reductions in pain at night, pain with activity, and functional improvement at 4 and 12 weeks with active but not sham TCPRFT. The 25 subjects who received active treatment showed statistically significant reductions of 24/100 in pain at night and 20/100 of pain with activity at 4 weeks and 18/100 and 19/100, respectively, at 12 weeks from baseline. Statistically significant lower Brief Pain Inventory pain and function scores (4 and 12 weeks), improved pain self‐efficacy (4 weeks), Oxford Shoulder scores (12 weeks), and internal rotation (12 weeks) were seen. Pain at both rest and shoulder elevation were not improved by active treatment. No complications were seen. This study of a simple, low risk, outpatient treatment confirms the findings of our earlier study of TCPRFT for knee pain and shoulder pain audit that transcutaneous pulsed radiofrequency treatment may help some people with painful shoulders. 相似文献
996.
997.
998.
999.